Cargando…
Microarray patches enable the development of skin-targeted vaccines against COVID-19
The COVID-19 pandemic is a serious threat to global health and the global economy. The ongoing race to develop a safe and efficacious vaccine to prevent infection by SARS-CoV-2, the causative agent for COVID-19, highlights the importance of vaccination to combat infectious pathogens. The highly acce...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060128/ https://www.ncbi.nlm.nih.gov/pubmed/33539853 http://dx.doi.org/10.1016/j.addr.2021.01.022 |
_version_ | 1783681300303970304 |
---|---|
author | Korkmaz, Emrullah Balmert, Stephen C. Sumpter, Tina L. Carey, Cara Donahue Erdos, Geza Falo, Louis D. |
author_facet | Korkmaz, Emrullah Balmert, Stephen C. Sumpter, Tina L. Carey, Cara Donahue Erdos, Geza Falo, Louis D. |
author_sort | Korkmaz, Emrullah |
collection | PubMed |
description | The COVID-19 pandemic is a serious threat to global health and the global economy. The ongoing race to develop a safe and efficacious vaccine to prevent infection by SARS-CoV-2, the causative agent for COVID-19, highlights the importance of vaccination to combat infectious pathogens. The highly accessible cutaneous microenvironment is an ideal target for vaccination since the skin harbors a high density of antigen-presenting cells and immune accessory cells with broad innate immune functions. Microarray patches (MAPs) are an attractive intracutaneous biocargo delivery system that enables safe, reproducible, and controlled administration of vaccine components (antigens, with or without adjuvants) to defined skin microenvironments. This review describes the structure of the SARS-CoV-2 virus and relevant antigenic targets for vaccination, summarizes key concepts of skin immunobiology in the context of prophylactic immunization, and presents an overview of MAP-mediated cutaneous vaccine delivery. Concluding remarks on MAP-based skin immunization are provided to contribute to the rational development of safe and effective MAP-delivered vaccines against emerging infectious diseases, including COVID-19. |
format | Online Article Text |
id | pubmed-8060128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80601282021-04-22 Microarray patches enable the development of skin-targeted vaccines against COVID-19 Korkmaz, Emrullah Balmert, Stephen C. Sumpter, Tina L. Carey, Cara Donahue Erdos, Geza Falo, Louis D. Adv Drug Deliv Rev Article The COVID-19 pandemic is a serious threat to global health and the global economy. The ongoing race to develop a safe and efficacious vaccine to prevent infection by SARS-CoV-2, the causative agent for COVID-19, highlights the importance of vaccination to combat infectious pathogens. The highly accessible cutaneous microenvironment is an ideal target for vaccination since the skin harbors a high density of antigen-presenting cells and immune accessory cells with broad innate immune functions. Microarray patches (MAPs) are an attractive intracutaneous biocargo delivery system that enables safe, reproducible, and controlled administration of vaccine components (antigens, with or without adjuvants) to defined skin microenvironments. This review describes the structure of the SARS-CoV-2 virus and relevant antigenic targets for vaccination, summarizes key concepts of skin immunobiology in the context of prophylactic immunization, and presents an overview of MAP-mediated cutaneous vaccine delivery. Concluding remarks on MAP-based skin immunization are provided to contribute to the rational development of safe and effective MAP-delivered vaccines against emerging infectious diseases, including COVID-19. The Author(s). Published by Elsevier B.V. 2021-04 2021-02-02 /pmc/articles/PMC8060128/ /pubmed/33539853 http://dx.doi.org/10.1016/j.addr.2021.01.022 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Korkmaz, Emrullah Balmert, Stephen C. Sumpter, Tina L. Carey, Cara Donahue Erdos, Geza Falo, Louis D. Microarray patches enable the development of skin-targeted vaccines against COVID-19 |
title | Microarray patches enable the development of skin-targeted vaccines against COVID-19 |
title_full | Microarray patches enable the development of skin-targeted vaccines against COVID-19 |
title_fullStr | Microarray patches enable the development of skin-targeted vaccines against COVID-19 |
title_full_unstemmed | Microarray patches enable the development of skin-targeted vaccines against COVID-19 |
title_short | Microarray patches enable the development of skin-targeted vaccines against COVID-19 |
title_sort | microarray patches enable the development of skin-targeted vaccines against covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060128/ https://www.ncbi.nlm.nih.gov/pubmed/33539853 http://dx.doi.org/10.1016/j.addr.2021.01.022 |
work_keys_str_mv | AT korkmazemrullah microarraypatchesenablethedevelopmentofskintargetedvaccinesagainstcovid19 AT balmertstephenc microarraypatchesenablethedevelopmentofskintargetedvaccinesagainstcovid19 AT sumptertinal microarraypatchesenablethedevelopmentofskintargetedvaccinesagainstcovid19 AT careycaradonahue microarraypatchesenablethedevelopmentofskintargetedvaccinesagainstcovid19 AT erdosgeza microarraypatchesenablethedevelopmentofskintargetedvaccinesagainstcovid19 AT falolouisd microarraypatchesenablethedevelopmentofskintargetedvaccinesagainstcovid19 |